| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.047 | 0.3 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.045 | 0.3 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.3 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.3 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | -0.12 | 0.3 |